



Food and Drug Administration
Rockville MD 20857

Re: Campath
Docket No.: 03E-0247

JUN 23 2004

The Honorable Jon Dudas
Acting Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Acting Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,545,403, filed by Millenium and Ilex Partners, L.P., under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Campath, the human biological product claimed by the patent.

The total length of the regulatory review period for Campath is 3,423 days. Of this time, 2,921 days occurred during the testing phase and 502 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this biologic product became effective: December 25, 1991.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on December 25, 1991.

2. The date the application was initially submitted with respect to the human biological product under section 351 of the Public Health Service Act: December 23, 1999.

The applicant claims December 22, 1999, as the date the product license application (BLA) for Campath (BLA 103948/0) was initially submitted. However, FDA records indicate that BLA 103948/0 was submitted on December 23, 1999.

3. The date the application was approved: May 7, 2001.

FDA has verified the applicant's claim that BLA 103948/0 was approved on May 7, 2001.


03E-0247

LET 3

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in cursive script, reading "Jane A. Axelrad".

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Scott A. Brown
Millenium Pharmaceuticals, Inc.
Patent Department
75 Sidney Street
Cambridge, MA 02139